BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 102 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q2 2014. The put-call ratio across all filers is 0.38 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2017 | $178,000 | -3.8% | 21,227 | -27.4% | 0.01% | 0.0% |
| Q4 2016 | $185,000 | +29.4% | 29,241 | -9.5% | 0.01% | +66.7% |
| Q3 2016 | $143,000 | +376.7% | 32,324 | +207.5% | 0.00% | +200.0% |
| Q2 2016 | $30,000 | -62.5% | 10,511 | -62.7% | 0.00% | -50.0% |
| Q1 2016 | $80,000 | -35.0% | 28,164 | +106.5% | 0.00% | -33.3% |
| Q1 2015 | $123,000 | -70.9% | 13,637 | -68.4% | 0.00% | -62.5% |
| Q3 2014 | $422,000 | +131.9% | 43,216 | +201.8% | 0.01% | +166.7% |
| Q2 2014 | $182,000 | +114.1% | 14,321 | +23.3% | 0.00% | +200.0% |
| Q3 2013 | $85,000 | – | 11,614 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| VHCP Management, LLC | 1,744,356 | $18,455,000 | 9.59% |
| RA Capital Management | 4,347,456 | $45,996,000 | 3.30% |
| Cormorant Asset Management, LP | 1,168,000 | $12,357,000 | 2.84% |
| Baker Brothers Advisors | 5,867,031 | $62,073,000 | 0.79% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 907,920 | $9,606,000 | 0.39% |
| QVT Financial LP | 525,734 | $5,562,000 | 0.32% |
| EAM Investors, LLC | 114,548 | $1,212,000 | 0.22% |
| FRANKLIN STREET ADVISORS INC /NC | 93,000 | $984,000 | 0.20% |
| THB ASSET MANAGEMENT | 301,529 | $3,190,000 | 0.19% |
| TPG Group Holdings (SBS) Advisors, Inc. | 1,162,269 | $12,297,000 | 0.13% |